(CercleFinance.com) – Euroapi announces an initial investment of 18 million euros for the implementation of state-of-the-art manufacturing equipment at its Frankfurt site, in order to meet the growing demand in the peptides segment and oligonucleotides.
This new equipment should make it possible to increase the site’s overall manufacturing capacity for peptides and oligonucleotides to nearly 500 kilos per year by 2025 and to envisage their future increase, subject to a limited investment.
This project also aims to strengthen Euroapi’s ability to become a long-term partner of pharmaceutical research companies, with services ranging from early development to marketing for new therapeutic platforms.